A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Clinical trial NCT06188520 · RECRUITING

Trial details

NCT number: NCT06188520
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

ER+ HER2- Advanced Breast Cancer High-grade Serous Ovarian Cancer (HGSOC)

Start date: 2023-12-05
Primary completion: 2027-08-04
Enrollment: 564

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.